{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:10:12Z","timestamp":1790885412487,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China.","doi-asserted-by":"crossref","award":["32360189"],"award-info":[{"award-number":["32360189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Project supported by the Young Scientists Fund of the National Natural Science Foundation of China","award":["82202034"],"award-info":[{"award-number":["82202034"]}]},{"name":"Guangzhou Science and Technology Plan Project","award":["2023A03J0273"],"award-info":[{"award-number":["2023A03J0273"]}]},{"name":"Xinjiang National science foundation science and technology aid project","award":["2022E02128"],"award-info":[{"award-number":["2022E02128"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-49614-9","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:55:24Z","timestamp":1777445724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ginkgetin enhances the antitumor effect of Taxol on human breast cancer MCF-7 cells via ferroptosis mediated by the MDM2\u2013p53\u2013YAP1 axis"],"prefix":"10.1038","volume":"16","author":[{"given":"Guangchao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaya","family":"Mahati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"11","key":"49614_CR1","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.trecan.2017.09.001","volume":"3","author":"SK Yeo","year":"2017","unstructured":"Yeo, S. K. & Guan, J. L. Breast cancer: Multiple subtypes within a tumor?. Trends Cancer 3(11), 753\u2013760 (2017).","journal-title":"Trends Cancer"},{"issue":"1","key":"49614_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/PAP.0000000000000232","volume":"27","author":"JYS Tsang","year":"2020","unstructured":"Tsang, J. Y. S. & Tse, G. M. Molecular classification of breast cancer. Adv. Anat. Pathol. 27(1), 27\u201335 (2020).","journal-title":"Adv. Anat. Pathol."},{"issue":"10074","key":"49614_CR3","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","volume":"389","author":"N Harbeck","year":"2017","unstructured":"Harbeck, N. & Gnant, M. Breast cancer. Lancet 389(10074), 1134\u20131150 (2017).","journal-title":"Lancet"},{"issue":"Suppl 1","key":"49614_CR4","doi-asserted-by":"publisher","first-page":"9s","DOI":"10.2967\/jnumed.115.157834","volume":"57","author":"ES McDonald","year":"2016","unstructured":"McDonald, E. S., Clark, A. S., Tchou, J., Zhang, P. & Freedman, G. M. Clinical diagnosis and management of breast cancer. J. Nucl. Med. 57(Suppl 1), 9s\u201316s (2016).","journal-title":"J. Nucl. Med."},{"issue":"6","key":"49614_CR5","first-page":"653","volume":"74","author":"A Roulot","year":"2016","unstructured":"Roulot, A. et al. Tumoral heterogeneity of breast cancer. Ann. Biol. Clin. (Paris) 74(6), 653\u2013660 (2016).","journal-title":"Ann. Biol. Clin. (Paris)"},{"issue":"6","key":"49614_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid, P. et al. Event-free survival with Pembrolizumab in early triple-negative breast cancer. N. Engl. J. Med. 386(6), 556\u2013567 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"49614_CR7","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2174\/1389557520999201214234421","volume":"21","author":"VM Dan","year":"2021","unstructured":"Dan, V. M., Raveendran, R. S. & Baby, S. Resistance to intervention: Paclitaxel in breast cancer. Mini Rev. Med. Chem. 21(10), 1237\u20131268 (2021).","journal-title":"Mini Rev. Med. Chem."},{"issue":"10","key":"49614_CR8","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.7150\/ijbs.60292","volume":"17","author":"H Yan","year":"2021","unstructured":"Yan, H. et al. Cisplatin induces pyroptosis via activation of MEG3\/NLRP3\/caspase-1\/GSDMD pathway in triple-negative breast cancer. Int. J. Biol. Sci. 17(10), 2606\u20132621 (2021).","journal-title":"Int. J. Biol. Sci."},{"issue":"7","key":"49614_CR9","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"Wright, J. J., Powers, A. C. & Johnson, D. B. Endocrine toxicities of immune checkpoint inhibitors. Nat. Rev. Endocrinol. 17(7), 389\u2013399 (2021).","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6","key":"49614_CR10","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","volume":"57","author":"KA Won","year":"2020","unstructured":"Won, K. A. & Spruck, C. Triple-negative breast cancer therapy: Current and future perspectives (Review). Int. J. Oncol. 57(6), 1245\u20131261 (2020).","journal-title":"Int. J. Oncol."},{"issue":"7","key":"49614_CR11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy, R. K. et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N. Engl. J. Med. 382(7), 597\u2013609 (2020).","journal-title":"N. Engl. J. Med."},{"key":"49614_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2020.111642","volume":"145","author":"M Adnan","year":"2020","unstructured":"Adnan, M. et al. Ginkgetin: A natural biflavone with versatile pharmacological activities. Food Chem. Toxicol. 145, 111642 (2020).","journal-title":"Food Chem. Toxicol."},{"key":"49614_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2020.153370","volume":"80","author":"JS Lou","year":"2021","unstructured":"Lou, J. S. et al. Ginkgetin derived from Ginkgetin biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2\/HO-1 axis in EGFR wild-type non-small-cell lung cancer. Phytomedicine 80, 153370 (2021).","journal-title":"Phytomedicine"},{"issue":"4","key":"49614_CR14","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/cbdd.13915","volume":"98","author":"L Wei","year":"2021","unstructured":"Wei, L., Jian, P., Erjiong, H. & Qihan, Z. Ginkgetin alleviates high glucose-evoked mesangial cell oxidative stress injury, inflammation, and extracellular matrix (ECM) deposition in an AMPK\/mTOR-mediated autophagy axis. Chem. Biol. Drug Des. 98(4), 620\u2013630 (2021).","journal-title":"Chem. Biol. Drug Des."},{"issue":"19","key":"49614_CR15","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1097\/CM9.0000000000003247","volume":"137","author":"A Alu","year":"2024","unstructured":"Alu, A. et al. Ginkgetin Ginkgo biloba derivative ginkgetin inhibits breast cancer growth by regulating the miRNA-122-5p\/GALNT10 axis. Chin Med J (Engl) 137(19), 2387\u20132389 (2024).","journal-title":"Chin Med J (Engl)"},{"key":"49614_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2024.117199","volume":"495","author":"Q Duan","year":"2025","unstructured":"Duan, Q. et al. Ginkgetin enhances breast cancer radiotherapy sensitization by suppressing NRF2-HO-1 axis activity. Toxicol. Appl. Pharmacol. 495, 117199 (2025).","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"4","key":"49614_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang, X., Stockwell, B. R. & Conrad, M. Ferroptosis: Mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Biol. 22(4), 266\u2013282 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"22","key":"49614_CR18","doi-asserted-by":"publisher","first-page":"7038","DOI":"10.1111\/febs.16059","volume":"289","author":"J Liu","year":"2022","unstructured":"Liu, J., Kang, R. & Tang, D. Signaling pathways and defense mechanisms of ferroptosis. FEBS J. 289(22), 7038\u20137050 (2022).","journal-title":"FEBS J."},{"issue":"13","key":"49614_CR19","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1016\/j.cell.2023.05.003","volume":"186","author":"D Liang","year":"2023","unstructured":"Liang, D. et al. Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones. Cell 186(13), 2748-2764.e22 (2023).","journal-title":"Cell"},{"issue":"5","key":"49614_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen, X., Kang, R., Kroemer, G. & Tang, D. Broadening horizons: The role of ferroptosis in cancer. Nat. Rev. Clin. Oncol. 18(5), 280\u2013296 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"49614_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103035","volume":"70","author":"M Shen","year":"2024","unstructured":"Shen, M. et al. DNAJC12 causes breast cancer chemotherapy resistance by repressing doxorubicin-induced ferroptosis and apoptosis via activation of AKT. Redox Biol. 70, 103035 (2024).","journal-title":"Redox Biol."},{"issue":"23","key":"49614_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202310309","volume":"11","author":"Y Li","year":"2024","unstructured":"Li, Y., Liu, J., Chen, Y., Weichselbaum, R. R. & Lin, W. Nanoparticles synergize ferroptosis and cuproptosis to potentiate cancer immunotherapy. Adv. Sci. (Weinh) 11(23), e2310309 (2024).","journal-title":"Adv. Sci. (Weinh)"},{"issue":"7","key":"49614_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12493","volume":"13","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. Baohuoside I chemosensitises breast cancer to paclitaxel by suppressing extracellular vesicle\/CXCL1 signal released from apoptotic cells. J. Extracell. Vesicles 13(7), e12493 (2024).","journal-title":"J. Extracell. Vesicles"},{"key":"49614_CR24","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.biopha.2017.09.077","volume":"96","author":"J Cao","year":"2017","unstructured":"Cao, J. et al. Ginkgetin inhibits growth of breast carcinoma via regulating MAPKs pathway. Biomed. Pharmacother. 96, 450\u2013458 (2017).","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"49614_CR25","first-page":"1245","volume":"19","author":"Y Ren","year":"2016","unstructured":"Ren, Y. et al. Ginkgetin induces apoptosis in 786-O cell line via suppression of JAK2-STAT3 pathway. Iran. J. Basic Med. Sci. 19(11), 1245\u20131250 (2016).","journal-title":"Iran. J. Basic Med. Sci."},{"key":"49614_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2022.101967","volume":"79","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y., Niu, Y. & Weng, Q. Ginkgetin promotes proliferation and migration of Schwann cells via PIGF\/p38 MAPK signaling pathway. Tissue Cell 79, 101967 (2022).","journal-title":"Tissue Cell"},{"issue":"4","key":"49614_CR27","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3892\/ijo.2017.4116","volume":"51","author":"YJ Lee","year":"2017","unstructured":"Lee, Y. J. et al. Ginkgetin induces G2-phase arrest in HCT116 colon cancer cells through the modulation of b-Myb and miRNA34a expression. Int. J. Oncol. 51(4), 1331\u20131342 (2017).","journal-title":"Int. J. Oncol."},{"issue":"9","key":"49614_CR28","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1016\/j.bmcl.2013.02.080","volume":"23","author":"OH You","year":"2013","unstructured":"You, O. H. et al. Ginkgetin induces apoptosis via activation of caspase and inhibition of survival genes in PC-3 prostate cancer cells. Bioorg. Med. Chem. Lett. 23(9), 2692\u20132695 (2013).","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"49614_CR29","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.3892\/ol.2017.6742","volume":"14","author":"Y Park","year":"2017","unstructured":"Park, Y. et al. Ginkgetin induces cell death in breast cancer cells via downregulation of the estrogen receptor. Oncol. Lett. 14(4), 5027\u20135033 (2017).","journal-title":"Oncol. Lett."},{"key":"49614_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18081733","author":"CH Yang","year":"2017","unstructured":"Yang, C. H. & Horwitz, S. B. Taxol(\u00ae): The first microtubule stabilizing agent. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms18081733 (2017).","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"49614_CR31","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1001\/jamaoncol.2021.1371","volume":"7","author":"A van der Voort","year":"2021","unstructured":"van der Voort, A. et al. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: A secondary analysis of the TRAIN-2 randomized, phase 3 trial. JAMA Oncol. 7(7), 978\u2013984 (2021).","journal-title":"JAMA Oncol."},{"issue":"4","key":"49614_CR32","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/ptr.6014","volume":"32","author":"H Lin","year":"2018","unstructured":"Lin, H. et al. Cytotoxicity of Tanshinone IIA combined with Taxol on drug-resist breast cancer cells MCF-7 through inhibition of Tau. Phytother. Res. 32(4), 667\u2013671 (2018).","journal-title":"Phytother. Res."},{"issue":"6","key":"49614_CR33","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00280-010-1455-1","volume":"66","author":"YK Shi","year":"2010","unstructured":"Shi, Y. K. et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer. Cancer Chemother. Pharmacol. 66(6), 1131\u20131140 (2010).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"49614_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2021.105200","volume":"75","author":"A Zajdel","year":"2021","unstructured":"Zajdel, A., Nycz, J. & Wilczok, A. Lapatinib enhances paclitaxel toxicity in MCF-7, T47D, and MDA-MB-321 breast cancer cells. Toxicol. Vitro 75, 105200 (2021).","journal-title":"Toxicol. Vitro"},{"issue":"12","key":"49614_CR35","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.3390\/cancers11121828","volume":"11","author":"WH Hu","year":"2019","unstructured":"Hu, W. H. et al. Synergy of ginkgetin and resveratrol in suppressing VEGF-induced angiogenesis: A therapy in treating colorectal cancer. Cancers 11(12), 1828 (2019).","journal-title":"Cancers"},{"issue":"8","key":"49614_CR36","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula, P., Zhuang, L. & Gan, B. Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell 12(8), 599\u2013620 (2021).","journal-title":"Protein Cell"},{"issue":"4","key":"49614_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1644","volume":"16","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. SLC40A1 in iron metabolism, ferroptosis, and disease: A review. WIREs Mech. Dis. 16(4), e1644 (2024).","journal-title":"WIREs Mech. Dis."},{"issue":"5","key":"49614_CR38","doi-asserted-by":"publisher","first-page":"jcs237453","DOI":"10.1242\/jcs.237453","volume":"133","author":"J Blagih","year":"2020","unstructured":"Blagih, J., Buck, M. D. & Vousden, K. H. p53, cancer and the immune response. J. Cell Sci. 133(5), jcs237453 (2020).","journal-title":"J. Cell Sci."},{"issue":"1","key":"49614_CR39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","volume":"14","author":"J Hu","year":"2021","unstructured":"Hu, J. et al. Targeting mutant p53 for cancer therapy: direct and indirect strategies. J. Hematol. Oncol. 14(1), 157 (2021).","journal-title":"J. Hematol. Oncol."},{"issue":"7\u20138","key":"49614_CR40","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1101\/gad.334219.119","volume":"34","author":"D Venkatesh","year":"2020","unstructured":"Venkatesh, D. et al. MDM2 and MDMX promote ferroptosis by PPAR\u03b1-mediated lipid remodeling. Genes Dev. 34(7\u20138), 526\u2013543 (2020).","journal-title":"Genes Dev."},{"issue":"1","key":"49614_CR41","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-020-01253-y","volume":"19","author":"J Lou","year":"2020","unstructured":"Lou, J. et al. Circular RNA CDR1as disrupts the p53\/MDM2 complex to inhibit gliomagenesis. Mol. Cancer 19(1), 138 (2020).","journal-title":"Mol. Cancer"},{"issue":"6","key":"49614_CR42","doi-asserted-by":"publisher","first-page":"511","DOI":"10.4161\/cbt.24345","volume":"14","author":"N Bai","year":"2013","unstructured":"Bai, N. et al. Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53. Cancer Biol. Ther. 14(6), 511\u2013520 (2013).","journal-title":"Cancer Biol. Ther."},{"issue":"7","key":"49614_CR43","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1111\/jcmm.16400","volume":"25","author":"S Ye","year":"2021","unstructured":"Ye, S. et al. Cytoglobin promotes sensitivity to ferroptosis by regulating p53-YAP1 axis in colon cancer cells. J. Cell. Mol. Med. 25(7), 3300\u20133311 (2021).","journal-title":"J. Cell. Mol. Med."},{"key":"49614_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.884362","volume":"13","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. YAP1 alleviates sepsis-induced acute lung injury via inhibiting ferritinophagy-mediated ferroptosis. Front. Immunol. 13, 884362 (2022).","journal-title":"Front. Immunol."},{"issue":"1","key":"49614_CR45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13578-022-00902-7","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. YAP1 protects against septic liver injury via ferroptosis resistance. Cell Biosci. 12(1), 163 (2022).","journal-title":"Cell Biosci."},{"issue":"7","key":"49614_CR46","first-page":"3357","volume":"12","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. Gentian violet induces apoptosis and ferroptosis via modulating p53 and MDM2 in hepatocellular carcinoma. Am. J. Cancer Res. 12(7), 3357\u20133372 (2022).","journal-title":"Am. J. Cancer Res."},{"key":"49614_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103362","volume":"77","author":"Z Xin","year":"2024","unstructured":"Xin, Z. et al. LncRNA-HMG incites colorectal cancer cells to chemoresistance via repressing p53-mediated ferroptosis. Redox Biol. 77, 103362 (2024).","journal-title":"Redox Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49614-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49614-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49614-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:02:02Z","timestamp":1782781322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49614-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["49614"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-49614-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The experimental protocols were approved by the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University (Approval Number: 20251023-05), and in compliance with the guidelines for the care and use of animals. I confirm that all methods are reported in accordance with ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"19865"}}